Critical Care Diagnostics, Inc.

Critical Care Diagnostics, Inc. specializes in developing advanced diagnostic solutions that enhance the care of critically ill patients through innovative biomarker technologies and testing services. Founded in 2004 by David Geliebter and Sven Jacobson, Critical Care Diagnostics, Inc. is based in San Diego, US.

The company focuses on innovative diagnostic solutions for critically ill patients. It has completed a total of 2 deals, with the most recent deal occurring on January 3, 2018, during which it raised USD 8. 5 mn in venture financing. Critical Care Diagnostics, Inc.

offers a suite of technology-driven diagnostic solutions aimed at improving patient care in critical settings. Their products include advanced biomarker testing services designed to aid healthcare providers in making timely and informed decisions regarding patient treatment. The company serves a diverse clientele, including hospitals and healthcare professionals, focusing on enhancing diagnostic accuracy and patient outcomes in critical care environments. The company generates revenue through a model where healthcare institutions pay for access to its diagnostic services.

This revenue stream is primarily derived from contracts with hospitals and healthcare providers, reflecting a stable financial foundation. Transactions typically occur directly between the firm and its clients, enabling tailored service offerings that cater to specific diagnostic needs. Moving forward, Critical Care Diagnostics, Inc. aims to expand its product offerings with upcoming diagnostic solutions planned for release in the next year.

Additionally, the company is targeting expansion into European and Asian markets by the end of 2023. The recent funding of USD 8. 5 mn will be utilized to accelerate product development and facilitate market entry strategies in these regions.